The DOI matches its Crossref record; the references it cites are not checked yet.
Pleiotropic Effects of Statins: Evidence Against Benefits Beyond LDL-Cholesterol Lowering
Abstract
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are extremely effective at reducing low-density lipoprotein (LDL) cholesterol and have been demonstrated to reduce mortality and the risk of major cardiovascular events in a number of large primary and secondary prevention studies. The linear relationship between LDL-cholesterol and cardiovascular risk suggests statins work solely by reducing LDL-cholesterol, and that ancillary properties do not contribute to cardiovascular risk reduction. In recent years, however, a number of additional non-lipid-lowering, or 'pleiotropic', effects of statins have been suggested to contribute to their efficacy in cardiovascular disease. The first data to suggest that statins may have benefits beyond lipid lowering came from the Heart Protection Study, in which simvastatin reduced mortality and morbidity even in patients with 'normal' LDL-cholesterol levels (2.6 mmol/L or 100 mg/dL). It has since been demonstrated, however, that cardiovascular risk remains high at this LDL concentration, but is substantially reduced in those achieving levels below 2.0 mmol/L (77 mg/dL). Evidence for the pleiotropic effects of statins in heart failure comes largely from retrospective and subgroup analyses of large studies. When statin therapy is compared with placebo, or when high-dose statin therapy is compared with low-dose treatment, a lower incidence of heart failure or hospitalization is observed. Despite promising retrospective data, ho…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the significance of these pleiotropic effects in clinical practice remains debated [37].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [37]
In the citing paper
“Studies show that policosanol from sugarcane, rice or wheat germ has no significant effect on LDL-C, HDL-C, TG, ApoB, Lp(a), homocysteine, high-sensitivity Creactive protein, fibrinogen, or blood coagulation factor levels [190].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [190]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 48 · Cited by 74
Research works printed but not linked: 1
- Leren, 1975, Acta Med Scand Suppl, 588, 1
Metadata
- Authors
- Pedersen, T. R.
- Affiliations
- Oslo University Hospital (NO)
- Corresponding author
- Pedersen, Terje R.
- ORCID
- Pedersen, Terje R.
- Venue
- American Journal Cardiovascular Drugs
- Published
- 2010-12
- Volume
- 10
- Pages
- 10-17
- ISSN
- 1175-3277 (ISSN-L)
- OpenAlex
- W217155269
- Semantic Scholar
- fb84158bb3a555af41cbc7b849298c80fd87ff5d
- Cited by
- 74
- References
- 48
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 1 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 5 · 2015: 1 · 2014: 4 · 2013: 11 · 2012: 4
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Cardiovascular Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- statins, pleiotropy, LDL cholesterol lowering, cardiovascular risk reduction, heart failure, endothelial function, atherosclerotic plaque, inflammation, antithrombotic activity, simvastatin, rosuvastatin, torcetrapib
- MeSH terms
- Animals, Anticholesteremic Agents, Cardiovascular Diseases, Heart Failure, Humans, Cholesterol, LDL, Myocardial Ischemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pleiotropic Effects of Statins: Evidence Against Benefits Beyond LDL-Cholesterol Lowering. https://app.cochat.ai/papers/10.2165/1158822-s0-000000000-00000
- The paper
- Pedersen, T. R. (2010). Pleiotropic Effects of Statins: Evidence Against Benefits Beyond LDL-Cholesterol Lowering. American Journal Cardiovascular Drugs. https://doi.org/10.2165/1158822-s0-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.